Sidewinder Therapeutics key facts
as of Oct 2026- Operator of a precision biologics development company intended to deliver new life-saving therapies for cancer and rare disease patients.
- Sidewinder Therapeutics is valued at approximately $204.0M as of Oct 2026 (last reported valuation).
- It has raised $161.0M; the latest was Early Stage VC ($137.0M) in Mar 2026.
- Notable investors include Alexandria Venture Investments, OrbiMed, Goldman Sachs Asset Management, Samsara BioCapital, Frazier Healthcare Partners — 9 tracked in total.
- Status: Privately Held (backing).
Sidewinder Therapeutics's last reported valuation, Mar 2026. Nothing priced has surfaced since.
- ·Watch Sidewinder Therapeutics: the Monday email on marks, rounds and moves
Sidewinder Therapeutics funding rounds
No funding rounds for Sidewinder Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Sidewinder Therapeutics valuation
Sidewinder Therapeutics's last reported valuation was $204 million in Mar 2026. No priced round, secondary trade or fund mark has surfaced since.
Sidewinder Therapeutics investors
9 investors are on record for Sidewinder Therapeutics, including Alexandria Venture Investments, OrbiMed, Goldman Sachs Asset Management and Samsara BioCapital.
About Sidewinder Therapeutics
Operator of a precision biologics development company intended to deliver new life-saving therapies for cancer and rare disease patients. The company offers medicines that target specific molecular drivers of disease, enabling customers to access new life-saving therapies for cancer and rare diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2023
- Employees
- 7
- Website
- sidewinderbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.